MiNK Therapeutics (INKT) and First Lviv Territorial Medical Union announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-797, MiNK’s off-the-shelf allogeneic invariant natural killer T cell therapy, in patients with severe acute lung injury. The study has received authorization from the Ministry of Health of Ukraine and is supported by an active U.S. IND.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer
- MiNK Therapeutics management to meet virtually with B. Riley
- MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
- MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
- INKT Upcoming Earnings Report: What to Expect?